-+ 0.00%
-+ 0.00%
-+ 0.00%

Press Release: Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update

Dow Jones·11/10/2026 11:30:00

Please log in to view news